ArriVent BioPharma Inc
AVBPHealthcare|Biotechnology|USA
$33.69
+0.02 (+0.06%)
Tangible Book
$7.15
About
ArriVent BioPharma Inc is a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. The company focuses on advancing its lead product candidate, firmonertinib, for the treatment of epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC), and developing a pipeline of novel therapeutics, including next-generation antibody-drug conjugates such as ARR-217 (MRG007), with an initial focus on solid tumors.
Stock Price
+52.9%(1Y)
Pipeline Summary
5 total trials2
Phase 1
0
Phase 2
3
Phase 3
0
Phase 4
Recruiting: 3Active: 2
Active Trials (5)
A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors
NCT07066657Locally Advanced or Metastatic Solid Tumors
Phase 1Recruiting
Enrollment: 405 participants
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
NCT07185997Non-Small-Cell Lung Cancer
Phase 3Recruiting
Enrollment: 480 participants
Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating, Including Uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Mutations
NCT05364073Non-Small Cell Lung Cancer (NSCLC)
Phase 1Active
Enrollment: 160 participants
Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT)
NCT05607550Metastatic Non-Small Cell Lung Cancer
Phase 3Active
Enrollment: 398 participants
A Study to Assess the Efficacy and Safety of Firmonertinib Versus Placebo for Adjuvant Treatment in Participants With Stage IB - IIIB NSCLC With Uncommon Epidermal Growth Factor Receptor (EGFR) Mutations, Following Complete Surgical Resection With or Without Adjuvant Chemotherapy（FIRMOST）
NCT07010419NSCLC
Phase 3Recruiting
Enrollment: 338 participants
BioScore
3.4/10
High Risk
Ownership
Recent Insider Trades
HILLHOUSE INVESTMENT MANAGEMENT, LTD.SELL
2025-12-10555,555 shares @ $23.37
ORBIMED ADVISORS LLCBUY
2024-01-30444,444 shares @ $18
HILLHOUSE INVESTMENT MANAGEMENT, LTD.BUY
2024-01-30555,555 shares @ $18
GORDON CARL LBUY
2024-01-30444,444 shares @ $18
Data last updated: Jul 13, 2026, 12:46 PM